Organization (Industry)
BioSensics (United States)
ClinicalTrials.gov lists BioSensics (United States) as lead sponsor of 12 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 8 registered with a 2026 start date. The dashed outline is the pace from the 6 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers BioSensics (United States): 12 lead-sponsored trials and 1 legal-entity registration.
Disease areas (27)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dementia | 11 |
| Cognitive Dysfunction | 5 |
| Alzheimer Disease | 3 |
| Corticobasal Degeneration | 3 |
| Frontotemporal Dementia | 3 |
Showing 5 of 27 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 8 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2015 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 1 hit target (n=1) | 2 of 2 on time (n=2) |
Journals published in (13)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Gerontology | 4 |
| Aging clinical and experimental research | 1 |
| Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases | 1 |
| BMC geriatrics | 1 |
| BMC neurology | 1 |
Showing 5 of 13 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 6 | 0 | 2018-02-27 |
Financing and grant events (41)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-04 | SBIR award | 1,064,194 | Reporter |
| 2025-08-28 | NIH grant | 5,174,076 | Reporter |
| 2025-07-23 | SBIR award | 1,245,820 | Reporter |
| 2025-06-03 | SBIR award | 50,000 | Reporter |
| 2024-11-22 | SBIR award | 973,917 | Reporter |
Showing 5 of 41 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| BIOSENSICS | Newton, US | FDA |
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 5 |
| Bijan Najafi, PhD | Co sponsors trial with | 2 |
| Harris Health System | Co sponsors trial with | 1 |
| Rancho Research Institute | Co sponsors trial with | 1 |
| Vanderbilt Health | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (76)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 76 events.
Biomarker capability evidence (8)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ATXN1 | Trial sponsor | Named in trial inclusion criteria |
| LRP4 | Trial sponsor | Named in trial inclusion criteria |
| MUSK | Trial sponsor | Named in trial inclusion criteria |
| MUSK | Trial collaborator | Named in trial inclusion criteria |
| ATXN1 | Trial sponsor | Mentioned in trial text |
Showing 5 of 8 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.